Higher HbA1c and/or glucose levels alter the association patterns between glycated hemoglobin and fasting glucose levels

et al. 2020

BMC Cardiovasc Disord

Background: The discrepancy between glycosylated hemoglobin (HbA 1c) and fasting plasma glucose (FPG) in clinical practice may be related to factors such as acute stress, renal dysfunction, and anemia, and its relationship with in-hospital outcomes is uncertain. The aim of this study was to investigate the association between the type of discrepancy between HbA 1c and FPG and in-hospital outcomes in patients with acute coronary syndrome (ACS) and diabetes. Methods: The Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS) project is a national, hospital-based quality improvement project with an ongoing database. Patients with ACS, diabetes and complete HbA 1c and FPG values at admission were included. The consistent group included patients with HbA 1c < 6.5% and FPG < 7.0 mmol/L or HbA 1c ≥ 6.5% and FPG ≥ 7.0 mmol/L. The discrepancy group included patients with HbA 1c ≥ 6.5% and FPG < 7.0 mmol/L (increased HbA 1c group) or HbA 1c < 6.5% and FPG ≥ 7.0 mmol/L (increased FBG group).

Section: Discussionsupporting

confidence: 66%

Admission fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project

et al. 2020

BMC Cardiovasc Disord

“…and FPG was present in approximately 30% of participants [21]. In our study, the discrepancy between HbA 1c and FPG was also found in patients with ACS and diabetes.…”

Section: Discussionsupporting

confidence: 68%

Admission fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the Improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project

et al. 2020

Preprint

BackgroundThe discrepancy between glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in clinical practice may be related to factors such as acute stress, renal dysfunction, and anemia, and its relationship with in-hospital outcomes is uncertain. The aim of this study was to investigate the association between the type of discrepancy between HbA1c and FPG and in-hospital outcomes in patients with acute coronary syndrome (ACS) and diabetes.MethodsThe Improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project is a national, hospital-based quality improvement project with an ongoing database. Patients with ACS, diabetes and complete HbA1c and FPG values at admission were included. The consistent group included patients with HbA1c < 6.5% and FPG < 7.0 mmol/L or HbA1c ≥ 6.5% and FPG ≥ 7.0 mmol/L. The discrepancy group included patients with HbA1c ≥ 6.5% and FPG < 7.0 mmol/L (increased HbA1c group) or HbA1c < 6.5% and FPG ≥ 7.0 mmol/L (increased FBG group).ResultsA total of 7,762 patients were included in this study. The numbers of patients in the consistent and discrepancy groups were 5,490 and 2,272 respectively. In the discrepancy group, increased HbA1c accounted for 77.5% of discrepancies, and increased FPG accounted for 22.5% of discrepancies. After adjusting for confounders, patients in the increased FPG group had a 1.6-fold increased risk of heart failure (OR, 1.62; 95% CI, 1.08-2.44), a 1.6-fold increased risk of composite cardiovascular death and heart failure (OR, 1.63; 95% CI, 1.09-2.43), and a 1.6-fold increased risk of composite major adverse cardiovascular and cerebrovascular events (MACCEs) and heart failure (OR, 1.56; 95% CI, 1.08-2.24) compared to patients in the increased HbA1c group.Conclusions Patients with an increased FPG but normal HbA1c had a higher risk of in-hospital adverse outcomes than those with increased HbA1c but normal FPG.This result may indicate that when HbA1c and FPG are inconsistent in patients with ACS and diabetes, the increased FPG that may be caused by stress hyperglycemia may have a more substantial adverse effect than increased HbA1c, which may be caused by chronic hyperglycemia. These high-risk patients should be given more attention and closer monitoring in clinical practice.

“…A study about the risk of hypertension in patients with prediabetes demonstrated the discrepancy between HbA 1c and FPG [20]. A study using data from residents of Yunnan Province, China, showed that the discrepancy between HbA 1c and FPG occurred in about 30% of participants [21]. In our study, the discrepancy between HbA 1c and FPG can be also found in patients with ACS and diabetes.…”

Section: Discussionsupporting

confidence: 68%

Type of discrepancy between glycosylated hemoglobin and fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the Improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) Project

et al. 2020

Preprint

Background The aim of this study is to investigate the association between types of discrepancy between glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) and in-hospital outcomes in patients with acute coronary syndrome (ACS) and diabetes, based on Improving Care for Cardiovascular Disease in China - acute coronary syndrome project. MethodsCCC-ACS project is a national, hospital-based quality improvement project. Patients with ACS, diabetes and complete HbA1c and FBG value at admission were included in this study. Patients were divided into consistent group and discrepancy group based on the HbA1c and FBG value at admission. Consistent group included patients with HbA1c < 6.5% and FBG < 7.0 mmol/L, or patients with HbA1c ≥ 6.5% and FBG ≥ 7.0 mmol/L. Discrepancy group included patients with HbA1c ≥ 6.5% and FBG < 7.0 mmol/L, or patients with HbA1c < 6.5% and FBG ≥ 7.0 mmol/L. Discrepancy group was further divided into increased HbA1c group (HbA1c ≥ 6.5% and FBG < 7.0 mmol/L) and increased FBG group (HbA1c < 6.5% and FBG ≥ 7.0 mmol/L).ResultsA total of 7,762 patients were included in this study. Patients in consistent group and discrepancy group were 5,490 (70.7%) and 2,272 (29.3%) respectively. In discrepancy group, increased HbA1c group accounted for 77.5% (1,761/2,272), and increased FPG group accounted for 22.5% (511/2,272). After adjusting for confounders by multivariate logistic regression model, patients in increased FPG group had a significantly 1.6-fold increased risk of heart failure (OR, 1.62; 95% CI, 1.08-2.44), a 1.6-fold increased risk of composite of cardiovascular death and heart failure (OR, 1.63; 95% CI, 1.09-2.43), and a 1.6-fold increased risk of composite of MACCE and heart failure (OR, 1.56; 95% CI, 1.08-2.24).Conclusions Patients with an increased level of FPG but normal HbA1c had a higher risk of in-hospital cardiovascular adverse outcomes than those with an increased level of HbA1c but normal FPG. These patients should be given more attention and closer monitoring in clinical practice in order to improve the in-hospital outcomes.